Therapeutic inhibition of RAS in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS mutations are key drivers in up to 30% of non-small cell lung cancer (NSCLC) cases.
• Previous direct KRAS-targeting strategies failed until the advent of covalent KRAS G12C inhibitors, approved for NSCLC in 2021.
• Recent advancements have introduced novel chemotypes to target KRAS mutations beyond the G12C allele.

Purpose of the Study:

• To review direct KRAS-targeting strategies in NSCLC treatment.
• To propose a classification schema for novel KRAS-targeting molecules based on chemical strategies.
• To evaluate the potential of various KRAS-targeting agents, including allele-specific, pan-KRAS, and pan-RAS inhibitors.

Main Methods:

• Recap of the chemistry and clinical strategy of KRAS G12C inhibitors.
• Development of a classification system for novel KRAS-targeting molecules (e.g., glues, degraders).
• Evaluation of non-G12C allele-specific inhibitors (e.g., G12D), pan-KRAS, and pan-RAS inhibitors.

Main Results:

• KRAS G12C inhibitors represent a significant first step in direct KRAS targeting for NSCLC.
• Emerging strategies include allele-specific inhibitors, pan-KRAS inhibitors, and pan-RAS inhibitors.
• These novel agents show potential in monotherapy and combination treatments with existing or new therapies.

Conclusions:

• The landscape of KRAS-targeted therapy in NSCLC is rapidly evolving beyond G12C.
• Novel pharmacologies like glues and degraders offer new avenues for KRAS inhibition.
• Future research will focus on optimizing combination strategies and exploring the full potential of these diverse KRAS-directed approaches in NSCLC.